These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33957633)

  • 1. BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort.
    Vassilakopoulou M; Won M; Curran WJ; Souhami L; Prados MD; Langer CJ; Rimm DL; Hanna JA; Neumeister VM; Melian E; Diaz AZ; Atkins JN; Komarnicky LT; Schultz CJ; Howard SP; Zhang P; Dicker AP; Knisely JPS
    Oncology; 2021; 99(9):580-588. PubMed ID: 33957633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.
    Blumenthal DT; Won M; Mehta MP; Gilbert MR; Brown PD; Bokstein F; Brachman DG; Werner-Wasik M; Hunter GK; Valeinis E; Hopkins K; Souhami L; Howard SP; Lieberman FS; Shrieve DC; Wendland MM; Robinson CG; Zhang P; Corn BW
    Neuro Oncol; 2018 Jun; 20(7):966-974. PubMed ID: 29462493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
    Younis SG; Khedr RA; El-Shorbagy SH
    J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of serum levels and tissue expression of two genes IGFBP-2 and IGFBP-3 act as potential biomarker for predicting the progression and survival in patients with glioblastoma multiforme.
    Abdolhoseinpour H; Mehrabi F; Shahraki K; Khoshnood RJ; Masoumi B; Yahaghi E; Goudarzi PK
    J Neurol Sci; 2016 Jul; 366():202-206. PubMed ID: 27288807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma.
    Liu B; Liu J; Liao Y; Jin C; Zhang Z; Zhao J; Liu K; Huang H; Cao H; Cheng Q
    Med Sci Monit; 2019 May; 25():3624-3635. PubMed ID: 31094363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of patients with multifocal glioblastoma: a case-control study.
    Patil CG; Yi A; Elramsisy A; Hu J; Mukherjee D; Irvin DK; Yu JS; Bannykh SI; Black KL; Nuño M
    J Neurosurg; 2012 Oct; 117(4):705-11. PubMed ID: 22920963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.
    Tsidulko AY; Kazanskaya GM; Kostromskaya DV; Aidagulova SV; Kiselev RS; Volkov AM; Kobozev VV; Gaitan AS; Krivoshapkin AL; Grigorieva EV
    Tumour Biol; 2017 Sep; 39(9):1010428317724282. PubMed ID: 28945172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid Early Tumor Progression is Prognostic in Glioblastoma Patients.
    Palmer JD; Bhamidipati D; Shukla G; Sharma D; Glass J; Kim L; Evans JJ; Judy K; Farrell C; Andrews DW; Wang ZW; Peiper SC; Werner-Wasik M; Shi W
    Am J Clin Oncol; 2019 May; 42(5):481-486. PubMed ID: 30973372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.
    Molitoris JK; Rao YJ; Patel RA; Kane LT; Badiyan SN; Gittleman H; Barnholtz-Sloan JS; Bentzen SM; Kruser TJ; Huang J; Mehta MP
    J Neurooncol; 2017 Sep; 134(2):331-338. PubMed ID: 28643151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.
    Michaelsen SR; Urup T; Olsen LR; Broholm H; Lassen U; Poulsen HS
    J Neurooncol; 2018 May; 137(3):533-542. PubMed ID: 29305787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.
    Smith DR; Wu CC; Saadatmand HJ; Isaacson SR; Cheng SK; Sisti MB; Bruce JN; Sheth SA; Lassman AB; Iwamoto FM; Wang SH; Canoll P; McKhann GM; Wang TJC
    J Neurooncol; 2018 Apr; 137(2):303-311. PubMed ID: 29264835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy.
    Li S; Zhang W; Chen B; Jiang T; Wang Z
    Neurol Res; 2010 Sep; 32(7):690-4. PubMed ID: 19703338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location.
    Woo P; Ho J; Lam S; Ma E; Chan D; Wong WK; Mak C; Lee M; Wong ST; Chan KY; Poon WS
    World Neurosurg; 2018 Jul; 115():e375-e385. PubMed ID: 29678708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme.
    Cetin B; Gonul II; Gumusay O; Bilgetekin I; Algin E; Ozet A; Uner A
    Neuropathology; 2018 Oct; 38(5):457-462. PubMed ID: 29952031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of care and predictors of adjuvant therapies in elderly patients with glioblastoma: An analysis of the National Cancer Data Base.
    Amsbaugh MJ; Yusuf MB; Gaskins J; Burton EC; Woo SY
    Cancer; 2017 Sep; 123(17):3277-3284. PubMed ID: 28452053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
    Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS
    J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of surgery on the efficacy of adjuvant therapy in glioblastoma multiforme.
    Brzozowska A; Toruń A; Mazurkiewicz M
    Adv Clin Exp Med; 2015; 24(2):279-87. PubMed ID: 25931361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hedgehog antagonist HHIP as a favorable prognosticator in glioblastoma.
    Chang L; Zhang P; Zhao D; Liu H; Wang Q; Li C; Du W; Liu X; Zhang H; Zhang Z; Jiang C
    Tumour Biol; 2016 Mar; 37(3):3979-86. PubMed ID: 26482617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.